ArticleBiomedicines2026

Upfront Versus Deferred CDK4/6 Inhibitor Use in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Real-World Study.

Pınar Kubilay Tolunay et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.